agsandrew / Shutterstock.com
The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops.
Research into genome-editing technologies has progressed to a point where we can read the strains of DNA that exist in almost every cell of our bodies as if they were on a word processor and take faulty, disease-causing genes out of a sequence and replace them with functioning ones.
The latest method of this so-called gene-editing technology is called CRISPR-Cas9. CRISPR-Cas9 gets its name from the clustered, regularly interspaced, short palindromic repeats (CRISPRs) in the DNA sequence, and the CRISPR-associated protein 9 (Cas9), which makes cuts in the specifically chosen locations in the strand.
Dubbed a ‘search and replace’ function for DNA, CRISPR-Cas9 allows researchers to easily make precise changes to a DNA sequence.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
CRISPR, patent, patent applications, DNA,